Prevalence of LDL atherogenic phenotype in patients with systemic lupus erythematosus

Vascular Health and Risk Management

Volumn 7, Issue 1, 2011, Pages 75-80

  Olusi, Samuel O ^a   George, Sunila ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

Atherosclerosis; Low density lipoprotein; Particle size; Systemic lupus erythematosus

Indexed keywords

APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DYSLIPIDEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GEL ELECTROPHORESIS; HUMAN; PARTICLE SIZE; PHENOTYPE; POLYMERIZATION; PREVALENCE; PROTEIN BLOOD LEVEL; QUALITY CONTROL; SYSTEMIC LUPUS ERYTHEMATOSUS; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; APOLIPOPROTEINS B; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; HUMANS; KUWAIT; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; PARTICLE SIZE; PHENOTYPE; PREVALENCE; REGRESSION ANALYSIS; TRIGLYCERIDES;

EID: 79951652702     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S17015     Document Type: Article

References (40)

1. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham study. Am J Epidemiol. 1997;145:408-415.
2. Petri M, Spence D, Bone LR, Hochberg MC. Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: Prevalence, recognition by patients and preventive practices. Medicine. 1992;71:291-302.
3. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001;44:2331-2337.
4. Bruce IN, Urowitz MB, Gladman DD, Hallett DC. Natural history of hypercholesterolemia in systemic lupus erythematosus. J Rheumatol. 1999;26:2137-2143.
5. Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum. 2002;46:2010-2019.
6. Fischer LM, Schlienger RG, Matter C, Jick H, Meier CR. Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction. Am J Cardiol. 2004;93:198-200.
7. Borba EF, Bonfa E. Dyslipoproteinemia in systemic lupus erythematosus: Influence of disease activity and anticardiolipin antibodies. Lupus. 1997;6:533-539.
8. Borba EF, Santos RD, Bonfa E, et al. Lipoprotein (a) levels in systemic lupus erythematosus. J Rheumatol. 1994;21:220-223.
9. Martínez-Berriotxoa A, Ruiz-Irastorza G, Egurbide MV, Rueda M, Aguirre C. Homocysteine, antiphospholipid antibodies and risk of thrombosis in patients with systemic lupus erythematosus. Lupus. 2004;13:927-933.
10. Frostegard J, Svenungssen R, Wu R, et al. Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal manifestations. Arthritis Rheum. 2005;52:192-200.
11. Selzer F, Sutton-Tyrrell K, Fitzgerald SG, et al. Comparison of risk factors for vascular disease in the carotid artery and aorta in women with systemic lupus erythematosus. Arthritis Rheum. 2004;50:151-159.
12. Lindgren FT, Jensen LC, Wills RD, Freeman NK. Flotation rates, molecular weights and hydrated densities of the low density lipoproteins. Lipids. 1969;4:337-344.
13. Adams GH, Schumaker VN. Polydispersity of human low-density lipoproteins. Ann N Y Acad Sci. 1969;164:130-146.
14. Hammond MG, Fisher WR. The characterisation of a discrete series of low-density lipoproteins in the disease, hyper-pre l-lipoproteinemia. J Biol Chem. 1971;246:5454-5455.
15. Lee DM. Isolation and characterization of low-density lipoproteins. In: Day CE, Levy RS, editors. Low Density Lipoproteins. New York, NY: Plenum Press; 1976.
16. Shen MS, Krauss RM, Lindgreeen FT, Forte TM. Heterogeneity of serum low-density lipoproteins in normal human subjects. J Lipid Res. 1981;22:236-244.
17. Baurowich GM, Dash J, Hensley WJ, Turtle JR. Gradient gel electrophoresis of human plasma lipoproteins. Clin Chem. 1973;19:415-418.
18. Campos H, Granest JJ Jr, Bilijievents E, et al. Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb. 1992;12:187-195.
19. Coresh J, Kwiteroviwich PO Jr, Smith HH, Bachorik PS. Association of plasma triglyceride concentration and LDL particle diameter, density and chemical composition with premature coronary artery disease in men and women. J Lipid Res. 1993;34:1887-1897.
20. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willet WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 1988;260:1917-1921.
21. Chung CP, Oeser A, Raggi P, et al. Lipoprotein subclasses and particle size determined by nuclear magnetic resonance spectroscopy in systemic lupus erythematosus. J Rheumatol. 2009;37:1633-1638.
22. Hua X, Su J, Svenungsson E, et al. Dyslipidaemia and lipoprotein pattern in systemic lupus erthematosus (SLE) and SLE-related cardiovascular disease. Scand J Rheumatol. 2009;38:184-189.
23. Friedwald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
24. Hoefner DM, Hodel SD, O'Brien JF, et al. Development of a rapid, quantitative method for LDL subfractionation with the use of the Quantimetrix Lipoprint LDL System. Clin Chem. 2001;47:266-274.
25. Kazumi T, Kawaguchi A, Hozumi T, et al. Low density lipoprotein particle diameter in young, nonobese, normolipidemic Japanese men. Atherosclerosis. 1999;142:113-119.
26. Muniz N, Duncan D, Neyer G. Normal reference ranges for serum lipoproteins and their subfractions for the LipoprintTM LDL System. Presented at the American Association of Clinical Chemistry, 53rd Annual Meeting, Chicago, IL; July 29-August 2, 2001.
27. Borba EF, Bonfa E. Dyslipoproteinemias in systemic lupus erythematosus: Influence of disease, activity, and anticardiolipin antibodies. Lupus. 1997;6:533-539.
28. Ilowite NT, Samuel P, Ginzler E, Jacobson MS. Dyslipoproteinemia in pediatric systemic lupus erythematosus. Arthritis Rheum. 1988;31:859-863.
29. Borba EF, Bonfa E, Vinagre CG, Ramires JA, Maranhao RC. Chylomicron metabolism is markedly altered in systemic lupus erythematosus. Arthritis Rheum. 2000;43:1033-1040.
30. Merrill JT, Rivkin E, Shen C, Lahita RG. Selection of a gene for apolipoprotein A1 using autoantibodies from a patient with systemic lupus erythematosus. Arthritis Rheum. 1995;38:1655-1659.
31. Dinu A, Merrill J, Shen C, Antonov I, Myones B, Lahita R. Frequency of antibodies to the cholesterol transport protein apolipoprotein A1 in patients with SLE. Lupus. 1998;7:355-360.
32. Petri M, Lakatta C, Magder L, Goldman D. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: A longitudinal data analysis. Am J Med. 1994;96:254-259.
33. Ettinger WH, Goldberg AP, Applebaum-Bowden D, Hazzard WR. Dyslipoproteinemia in systemic lupus erythematosus: Effect of corticosteroids. Am J Med. 1987;21:1264-1267.
34. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation. 1990;82:495-506.
35. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet. 1994;344:793-795.
36. Wu R, Huang YH, Elinder LS, Frostgard J. Lysophosphatidyl choline is involved in the antigenicity of oxidized LDH. Arterioscler Thromb Vasc Biol. 1998;18:626-630.
37. Binder CJ, Chang MK, Shaw PX, et al. Innate and acquired immunity in atherogenesis. Nat Med. 2002;8:1218-1226.
38. Horkko S, Bird DA, Miller E, et al. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipids-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J Clin Invest. 1999;103:117-128.
39. Steinberg D. Atherogenesis in perspective: Hypercholesterolemia and inflammation as partners in crime. Nat Med. 2002;8:1211-1217.
40. Glass CK, Witztum JL. Atherosclerosis: The road ahead. Cell. 2001;104:503-516.